Background and aims: HIV-1 RNA viral load (VL) in plasma samples of HIV-1-positive
| INTRODUCTION
The introduction of new antiretroviral agents in the last decade has significantly improved the efficacy and safety of antiretroviral therapy (ART) in HIV-1-infected patients. 1 Besides clinical and immunological monitoring, which are used as complementary evaluations, HIV-1 RNA quantitation in patients' plasma samples is currently considered the main approach to monitor ART compliance and success. [2] [3] [4] Optimal control of HIV-1 infection is reached when the complete viral suppression achieved persists over time. Even if full viral suppression is achievable in most patients (both treatment-naïve and experienced), some show a transient, low viremia ("blips"). 5, 6 Some blips might be considered artifactual variations in viral load (VL) because of assay variability and laboratory processing inconsistencies, 7 
| HIV-1 samples
The 335 plasma samples collected in EDTA tubes were tested side-byside in the Aptima-HIV-1 and CAP/CTM2 assays, without further criteria for selection other than available sample volume.
Tubes were centrifuged for 10 minutes at 1000 to 3000 g for plasma preparation. All samples were first tested with the CAP/ CTM2 assay.
If the residual plasma volume was ≥1.2 mL, the same samples were immediately tested in primary tubes on the Hologic Panther instrument. For samples with less than 1.2 mL residual plasma volume, 0.70 mL plasma was transferred to Hologic specimen aliquot tubes.
Among the samples evaluated in the study, 248 specimens were derived from HIV-1 patients infected with B HIV-1 strains and 87 samples from other subtypes (A, C, F, G, and CRFs), characterized by phylogenetic analysis of HIV-1 pol gene (RT and PR). 14, 15 In particular, 12 samples belonged to subtypes A, 9 to subtypes C, 23 to subtypes F, 14 to subtypes G, and 29 were circular recombinant forms (CRFs).
| HIV-1 VL assays
Samples in the 2-assay platforms were processed and tested by trained operators, by Aptima HIV-1 Quant Dx assay (cat. no. PRD-03000) and
Roche CAP/CTM2 (cat. no. 05212294190) according to the assay manufacturers' package inserts.
| Aptima-HIV-1 assay
All the samples were tested in specimen aliquot tubes. Samples were loaded onto the Panther system (Hologic, Inc). HIV-1 genomic RNA was first released using target capture technology and then bound to magnetic particles. The Aptima HIV-1 Quant assay uses the TMA method to amplify 2 regions of HIV-1 RNA (pol and LTR) from the sample and amplifies and detects the amplified targets, all in an automated manner.
The assay's reported lower limit of quantification (LLOQ) is 1.47 log copies/mL, and its upper limit of quantitation is 7 log copies/mL (Hologic Inc, PI). The reported limit of detection (LoD) of the Aptima-HIV-1 assay is 12 cp/mL. Panther system allows random access testing of various analytes, processing up to 275 samples in an 8-hour shift.
The system provides results from 120 samples in about 2.5 hours.
| CAP/CTM2 assay
All the samples were tested in Roche S-tubes. The sample volume used was 1 mL. 14, 15 were serially diluted to 4 target concentrations (about 2.5 to about 5.5 log copies/ mL). Five replicates of each dilution were tested in the Aptima-HIV-1 assay on 3 separate days, after storage at 4°C.
| Data analyses
VL values were expressed as log copies/mL. Agreement of the assays' qualitative results (ie, defining samples as "negative,"
"detected <LLOQ," and "quantitated") was determined using a tabular format. For a very small number of plasma samples with discordant results between the 2 assays (eg, negative or detected <LLOQ in one assay and quantitated in the other assay), the patients' immunological data CD4 count and CD4/CD8 ratio, determined as previously described, 15 were considered. 3 | RESULTS
| Assay performance comparison in clinical samples
Assay performance was compared using all 335 clinical samples (248 HIV-1 type B and 87 HIV-1 non-B samples) with VLs identified by CAP/CTM2, ranging from undetectable (105/335) to detectable HIV-1 RNA amounts (up to 7 log copies/mL). The numbers in circles indicate the agreement between the assays' qualitative results. Highlighted in gray are the CAP/CTM2 results, which are discordant with the Aptima-HIV result.
Abbreviation: TND, target not detected.
As shown in Table 1 log copies/mL (by 0.05 log) and greater than CAP/CTM2 values for VLs ≥2 log ( Figure 1B ). Absolute differences between assay quantitative values were the highest (0.49 log copies/mL) for samples with high VLs (>5 log copies/mL) and lowest (0.02 to 0.05) for samples with VLs <4 log copies/mL (data not shown). Overall, 96.3% (158/ 164) of the results were within the 95% limit of agreement of the assays (−0.42 to +0.86 log copies/mL) ( Figure 1B ). Of the 6 outlier samples (outside the limit of agreement), three differed by <0.5 log in both assays, one differed by >0.5 log but <1 log, and two by >1 log but <1.5 log.
As shown in Table 1 Among these 20 samples with discordant results (Table 2A), 14 showed <30 copies/mL HIV-1 RNA by Aptima and detectable viral replication under 50 copies/mL (ranging from 31 to 47 copies/mL) by CAP/CTM2. The remaining 6 samples (patients [15] [16] [17] [18] [19] [20] presented <LLOQ levels (sample [15] [16] [17] [18] or undetectable results by Aptima-HIV-1 (patients [19] [20] , and VLs ranging from 53 to 255 by CAP/CTM2.
Particular attention was given to these last 6 samples (Table 2AB) Abbreviations: cp/mL, copies/mL; TND, target not detected.
detectable value of VL (84, 102, and 113 copies/mL, respectively), as determined by CAP/CTM2 VL results, accompanied, in further samples, by a clear improvement in immunological parameters.
| HIV-1 subtypes
Results obtained by the analysis of 87 samples from HIV-1 patients infected with subtypes A, C, F, G, and CRFs showed that similar findings could be obtained from samples derived from HIV-1-infected subjects with subtypes A and C, irrespective of HIV-1 RNA amounts, with no significant difference between the assays used. On the other hand, Aptima HIV-1 Quant DX assay was able to detect higher level of viral replication in samples containing HIV-1 subtype F, G, and CRFs, revealing important differences (≥0.5 log) in 13 samples (5 belonging to subtype F, 3 to subtype G, 5 to CRFs), as shown in Table 3 .
| Assay accuracy with a standard panel
The assays' ability to accurately quantitate HIV-1 RNA at low VLs was evaluated using the Acrometrix standard at target concentrations ranging from 1.2 to 2.8 log copies/mL. Assay results showed a very good precision, with all assay results differing by <0.5 log copies/ mL from the target values, and excellent linearity (R 2 ≥ 0.94) (Figure 2 ).
| Repeatability, reproducibility, precision, and linearity with patient's samples of 2 subtypes
Two well-characterized 14, 15 clinical samples (subtype B and F) were tested by Aptima-HIV-1 to determine within-run repeatability, between-run reproducibility, precision, and linearity of the assay.
Within-run repeatability was substantially good, as reflected by an SD ≤0.16 for the 5 replicates tested (Table 4) 
| DISCUSSION
As HIV-1 VL monitoring has become the cornerstone for the management of HIV-1-positive patients during their lifelong treatment regimen(s), the assays used to measure HIV-1 VL must be highly sensitive, specific, accurate, and precise. In the present study, the TMA-based Aptima-HIV-1 assay demonstrated sensitivity, reproducibility, and precision for the detection and quantitation of HIV-1-RNA across a wide dynamic range of VLs (including very low VLs).
Assay agreement for qualitative results in 335 clinical samples was fair (80.6%). Quantitative results for Aptima-HIV-1 and CAP/CTM were highly correlated (R 2 = 0.97) and only 2 of 164 samples quantitated by both assays had results that differed by >1 log copies/mL but <1.5 log copies/mL. Although Aptima-HIV-1 results were on average slightly higher than CAP/CTM2 results (by 0.22 log), the difference between assay results was minimal at low VLs (0.05 at VLs 1-1.99 log;
0.04 at VLs 2-2.99 log, and 0.02 at VLs 3-3.99 log).
Among the 65 discordant results, most samples did not show substantial variations. Indeed, in 45 samples the differences were very small (less than 30 or 20 copies/mL by one test and undetectable by the other test) and may not be considered as real conflicting results.
In fact, optimal viral suppression is generally defined as a VL persistently below the level of detection (HIV RNA <20 to 75 copies/mL, depending on the assay used). detectable VL of 50 to 400 copies/mL is preceded or followed by an undetectable result, testing the sample again is recommended to avoid an assay artifact or to establish a true viral rebound. [16] [17] [18] Moreover, the occurrence of so called viral blips (50-400/1000 copies/mL) during treatment are important events, which could be misinterpreted as treatment failure and hence may lead to a change in medication, since the goal of ART is VL suppression to TND or <50 copies/mL.
While we cannot rule out the probability that proviral HIV-1 genomic sequences in the plasma could be responsible for the blips (eg, originating from latently infected cells in the pellet), the small number of samples prevents any definitive conclusion.
Our results concur with those of other studies that found the Aptima-HIV-1 assay to have a performance comparable with the CAP/CTM2 test. [19] [20] [21] [22] [23] [24] [25] [26] Several data [19] [20] [21] [22] 25 showed a small (<0.23 log) positive bias for Aptima-HIV-1 VLs, whereas one study found a small (0.075) negative bias. 23 Yet another study found Aptima-HIV-1 to be more sensitive than CAP/CTM2. 27 Aptima-HIV-1 has also been shown to have performance characteristics similar to 19, 28, 29 The Aptima assay demonstrated good performance, sensitivity, precision, and reliability, in addition to an excellent clinical agreement.
Combined with full automation, high throughput, and superior workflow, 31 Aptima-HIV-1 is suitable for VL monitoring of HIV-1 patients during treatment. 
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